Registered title, quoted from ClinicalTrials.gov
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06830889, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Patients with histologically confirmed HER2-positive invasive breast cancer;
Inclusion criterion 4
The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;
Inclusion criterion 6
Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;
Inclusion criterion 5
The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
Inclusion criterion 12
Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy;
Exclusion criterion 6
Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose > 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride > 480 mg/m2;
Exclusion criterion 8
ECOG score 0 or 1;
Inclusion criterion 11
Other primary malignancies diagnosed within 5 years before the first dose;
Exclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06830889, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Sign the informed consent form voluntarily and follow the protocol requirements;
- Women aged ≥18 years and ≤75 years at the time of written informed consent;
- Expected survival time ≥6 months;
- Patients with histologically confirmed HER2-positive invasive breast cancer;
- Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;
- The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;
- Previous neoadjuvant therapy should meet the prescribed treatment conditions;
- Had received radical mastectomy;
- Determine hormone receptor (HR) status;
- The interval between radical surgery and randomization was at least 3 weeks and at most 12 weeks;
- ECOG score 0 or 1;
- The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
- No blood transfusion within 14 days before the first use of the study drug and no use of colony-stimulating factors were allowed;
- For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients should use adequate and highly effective contraception during the entire treatment cycle and for 7 months after the end of treatment.
Exclusion Criteria:
- A diagnosis of stage IV metastatic breast cancer was made;
- Bilateral breast cancer;
- Any previous history of breast cancer (unilateral or contralateral) except for lobular carcinoma in situ (LCIS);
- Evidence of clinically significant residual disease or recurrent or metastatic disease after neoadjuvant therapy and surgery;
- Other primary malignancies diagnosed within 5 years before the first dose;
- Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy;
- Subjects are participating in other clinical studies and receiving anti-tumor treatment;
- Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose > 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride > 480 mg/m2;
- History of severe cardiovascular or cerebrovascular disease within six months before screening;
- QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Poorly controlled hypertension (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg);
- Complicated with pulmonary diseases leading to severe impairment of lung function;
- A history of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia, or suspected such disease during screening; CTCAE v5.0 was used to define grade ≥3 pulmonary disease and grade ≥2 radiation pneumonitis;
- Human immunodeficiency virus antibody (HIVAb) positive, active hepatitis B virus infection, liver cirrhosis, or hepatitis C virus infection;
- Had a serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening;
- Were receiving \> within 2 weeks before the first dose; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;
- Patients with a history of severe allergy to recombinant humanized antibodies or to any of the excipents of BL-M07D1;
- Known hypersensitivity or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known contraindications to T-DM1;
- Had a history of autologous or allogeneic stem cell transplantation or organ transplantation;
- Have a severe neurological or psychiatric illness;
- Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
- Subjects scheduled to receive live vaccine or within 28 days before the first dose;
- Patients with other serious physical and laboratory abnormalities or poor adherence that may increase the risk of participating in the study, or interfere with the results of the study, and patients who were deemed by the investigators to be unsuitable for participation in the study.
Quoted from ClinicalTrials.gov, NCT06830889, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06830889, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.